Skip to main content

Table 3 The Committee’s and the sample ranking of technologies evaluated by the 2006/7 Basket Committee (monthly cost threshold = 250 NIS)

From: Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?

Technology Committee’s inclusion decision Rank Basket Committee Rank survey - Total Rank survey - Physicians Rank survey - Members of any Basket Committee Rank efficiencya
Crestor Ezetrol YES 1 28 28 25 12
Atacand Ocsaar Diovan Olmetec YES 2 28 28 25 3
Lantus Levemir YES 3 17 17 14 5
Apidra Humalog Novorapid YES 4 28 28 25 9
Eloxatin YES 5 14 14 14 4
Xeloda YES 6 14 14 14 1
Herceptin YES 7 10 10 11 23
Hepsera YES 8 2 2 2 16
Viread YES 9 9 7 7 22
Prevnar YES 10 32 32 32 32
Mabthera YES 11 1 1 1 14
Keppra YES 12 20 20 24 28
Zyprexa YES 13 21 21 22 6
Exjade YES 14 4 4 3 19
Plavix (cardiac) YES 15 7 7 4 10
Growth hormon YES 16 13 13 10 13
Plavix (stroke) YES 17 7 7 4 8
Velcade YES 18 3 3 4 27
Zomera NO 26.5 10 10 11 29
Apo-Go NO 26.5 5 5 8 21
Azilect NO 26.5 5 5 8 17
Cetuximab (Erbitux®) NO 26.5 25 25 25 31
Doxil NO 26.5 14 14 14 11
Emend NO 26.5 33 33 33 33
Erlotinib (Tarceva®) NO 26.5 25 25 25 30
Faslodex NO 26.5 10 10 11 24
Forteo NO 26.5 27 27 25 34
Gardasil NO 26.5 23 23 19 20
Lucentis NO 26.5 17 17 14 18
Rimonabant (Acomplia®) NO 26.5 34 34 34 25
Sifrol NO 26.5 19 19 21 26
Spiriva NO 26.5 28 28 25 7
Zemplar NO 26.5 21 21 22 15
Zyban NO 26.5 23 23 19 2
Mean rank YES 9.5 14.3 14.2 13.4 14.0
NO 26.5 19.9 19.9 19.6 21.4
  1. aBy international data on cost per QALY gained